Treatment of Postprandial Distress Syndrome and Epigastric Pain Syndrome with Mosapride: A Randomized, Double-blind, Placebo-controlled Study

JI Jieru,GAO Wei,XU Ping,WANG Tianrong,CHEN Shengliang

DOI: https://doi.org/10.3969/j.issn.1008-7125.2008.11.004

2008-01-01

Abstract:Background: As a prokinetic agent, mosapride has been used for treatment of functional dyspepsia (FD) for a long time. However, there are few studies reported on clinical therapeutic trial of mosapride for FD according to Rome Ⅲ criteria. Aims: To investigate the therapeutic effect and safety of mosapride on postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Methods: Eighty-three patients with documented PDS and EPS based on Rome Ⅲ criteria of FD in Outpatient Department at Gastroenterology of Shanghai Renji Hospital, from December 2006 to September 2007 were enrolled. All patients were at first given placebo for one week. If no response was observed, patients were then allocated to treatment process A or B to receive mosapride 5 mg tid or placebo 1 pill tid for one week randomly. After a one-week wash-out period with placebo 1 pill tid, finally, they were given placebo 1 pill tid or mosapride 5 mg tid for the last investigating week. Before and after each treatment period, the FD symptoms were evaluated. Results: The total effectiveness rate of placebo was 19.3% (16/83), 34 and 33 patients with no response to placebo were randomized to treatment processes A and B. Compared with the placebo-treated patients, mosapride therapy decreased significantly the total symptoms score (14.4±6.8 vs. 1.4±1.3, P<0.05), and had marked therapeutic effect on the bothersome postprandial fullness and early satiety in PDS, as well as on the pain and burning sensation localized to epigastrium in EPS. The effectiveness rates of mosapride on PDS and EPS were 79.4% and 60.6% (P<0.05), respectively. Conclusions: Mosapride therapy markedly improves the clinical symptoms of both PDS and EPS, and the effectiveness rate is greater on PDS than on EPS. It is safe and effective in the treatment of FD.